carbamazepine has been researched along with Adverse Drug Event in 95 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "IV carbamazepine administered as multiple 30- or 15-min infusions every 6 h, and as a single rapid infusion, was well tolerated as a short-term replacement in adults with epilepsy receiving stable dosages of oral carbamazepine." | 9.20 | Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials. ( Bekersky, I; Biton, V; Cloyd, J; Dheerendra, S; Halford, JJ; Kalu, U; Klein, P; Lee, D; Peng, G; Tolbert, D, 2015) |
| "In this phase 1, open-label study, adult patients with epilepsy on a stable oral carbamazepine dosage (400-2,000 mg/day) were converted to intravenous carbamazepine (administered at 70% of the oral dosage)." | 9.20 | Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. ( Bekersky, I; Biton, V; Cloyd, J; Drummond, R; Lee, D; Tolbert, D; Walzer, M; Wesche, D, 2015) |
| "The aim of this study was to evaluate the safety and efficacy of extended release carbamazepine (CBZ-ER) monotherapy in the treatment of pediatric bipolar disorder (BD)." | 9.14 | A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. ( Aleardi, M; Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Walls, S; Williams, C; Wozniak, J, 2010) |
| "Routine testing for HLA-A*31:01 in order to reduce the incidence of cutaneous adverse drug reactions in patients being prescribed carbamazepine for epilepsy is likely to represent a cost-effective use of health care resources." | 7.81 | Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. ( Alfirevic, A; Hughes, DA; Marson, AG; Pirmohamed, M; Plumpton, CO; Yip, VL, 2015) |
| "This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC." | 5.62 | Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jang, Y; Kim, TJ; Lee, S; Lee, SK; Yoon, S; Yu, KS, 2021) |
| "IV carbamazepine administered as multiple 30- or 15-min infusions every 6 h, and as a single rapid infusion, was well tolerated as a short-term replacement in adults with epilepsy receiving stable dosages of oral carbamazepine." | 5.20 | Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials. ( Bekersky, I; Biton, V; Cloyd, J; Dheerendra, S; Halford, JJ; Kalu, U; Klein, P; Lee, D; Peng, G; Tolbert, D, 2015) |
| "In this phase 1, open-label study, adult patients with epilepsy on a stable oral carbamazepine dosage (400-2,000 mg/day) were converted to intravenous carbamazepine (administered at 70% of the oral dosage)." | 5.20 | Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. ( Bekersky, I; Biton, V; Cloyd, J; Drummond, R; Lee, D; Tolbert, D; Walzer, M; Wesche, D, 2015) |
| "The aim of this study was to evaluate the safety and efficacy of extended release carbamazepine (CBZ-ER) monotherapy in the treatment of pediatric bipolar disorder (BD)." | 5.14 | A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. ( Aleardi, M; Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Walls, S; Williams, C; Wozniak, J, 2010) |
| " Exanthema as especially clinically relevant adverse drug event was rightly chosen for carbamazepine by 18 (8%) and for lamotrigine by 12 (5%) participants." | 4.02 | Knowledge of epilepsy among German pharmacists. ( Bertsche, A; Bertsche, T; Herziger, B; Jeschke, S; Müller, RM; Neininger, MP, 2021) |
| "Routine testing for HLA-A*31:01 in order to reduce the incidence of cutaneous adverse drug reactions in patients being prescribed carbamazepine for epilepsy is likely to represent a cost-effective use of health care resources." | 3.81 | Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. ( Alfirevic, A; Hughes, DA; Marson, AG; Pirmohamed, M; Plumpton, CO; Yip, VL, 2015) |
| "We evaluated the cost and efficiency of routine HLA-B*15 ∶ 02 screening to prevent carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (CBZ-SJS/TEN) in Hong Kong." | 3.80 | Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions. ( Chen, Z; Kwan, P; Liew, D, 2014) |
| " We present a case of Stevens-Johnson syndrome in a patient treated with carbamazepine." | 3.79 | A clinical approach to pharmacogenetics. ( de Graaff, LC; van Gelder, T; van Schaik, RH, 2013) |
| "There is strong evidence of an association between the presence of the human leukocyte antigen (HLA)-B*15:02 and two severe adverse drug reactions-Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)-in patients taking carbamazepine (CBZ), a common treatment for patients with epilepsy and neuropathic pain." | 3.79 | Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. ( Koopitakkajorn, T; Mahasirimongkol, S; Praditsitthikorn, N; Rattanavipapong, W; Teerawattananon, Y, 2013) |
| "Carbamazepine, an anticonvulsant and a mood-stabilizing drug, is the main cause of the Stevens-Johnson syndrome (SJS) and its related disease, toxic epidermal necrolysis (TEN), in Southeast Asian countries." | 3.77 | Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. ( Chang, CF; Chen, CH; Chen, L; Chen, P; Chen, YJ; Chen, YT; Chu, CC; Chuang, HP; Chung, WH; Hsieh, PF; Hsu, YC; Huang, LC; Hung, SI; Lan, SH; Liao, HT; Lin, JJ; Lin, SY; Lin, YH; Lu, CH; Lu, CS; Lu, CT; Ong, CT; Ro, LS; Shen, CY; Su, YH; Sung, SF; Tai, CT; Tsai, JJ; Tsai, PJ; Wu, JY; Wu, SL; Yang, CC; Yu, HY, 2011) |
| "An increased risk for isolated CL/P was found in cases born to mothers treated with amoxicillin, phenytoin, oxprenolol, and thiethylperazine during the second and third month of pregnancy, i." | 3.74 | Drug treatment during pregnancy and isolated orofacial clefts in hungary. ( Czeizel, AE; Métneki, J; Puhó, EH; Szunyogh, M, 2007) |
| "Pharmacogenomics (PGx) is a research area aimed at identifying genetic factors that are associated with drug responses, including drug efficacy, adverse drug reactions, and the appropriate drug dosage on a case-to-case basis." | 3.01 | Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics. ( Mushiroda, T, 2023) |
| "A generalized tonic-clonic seizure (GTCS) is the most severe form of common epileptic seizure and carries the greatest risk of harm." | 2.58 | Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection. ( Bermejo, PE; Gibbs, AA; Huberfeld, G; Kälviäinen, R; Shorvon, SD, 2018) |
| "Oxcarbazepine (OXC) is a drug that has a similar structure of carbamazepine." | 2.58 | Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis. ( Liu, Y; Nie, X; Wang, X; Yu, Y; Zhao, L, 2018) |
| "Carbamazepine (CBZ) is a first-line widely used anticonvulsant." | 2.50 | Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response. ( Cook, HJ; Galindo, IF; Jaramillo, NM; LLerena, A; López, ML; Vázquez, AO, 2014) |
| "Data on epilepsy syndrome, duration, seizure types, concomitant and previous antiseizure medication (ASM) use, BRV dosing, efficacy, and side effects were recorded." | 1.72 | Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center. ( Green, SF; Hare, N; Kassam, M; Koepp, MJ; Rajakulendran, S; Rugg-Gunn, F; Sander, JW, 2022) |
| "Lithium carbonate was associated with increased risks of rash (PT), drug interaction (PT), and tubulointerstitial diseases (SMQ)." | 1.72 | Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database. ( Nabekura, T; Uwai, Y, 2022) |
| "This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC." | 1.62 | Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jang, Y; Kim, TJ; Lee, S; Lee, SK; Yoon, S; Yu, KS, 2021) |
| " Safety and tolerability were assessed throughout follow-up by evaluating adverse events (AEs) and ESL discontinuation due to AEs, respectively." | 1.56 | Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. ( Assenza, G; McMurray, R; Peltola, J; Rocamora, R; Villanueva, V, 2020) |
| "Eight years after the index seizure, 31 % of the children were on AEDs, and this was more common among children with any of the comorbidities studied (OR; 4." | 1.56 | Childhood-onset seizures: A long-term cohort study of use of antiepileptic drugs, and drugs for neuropsychiatric conditions. ( Åmark, P; Åndell, E; Carlsson, S; Pihlström, N; Tedroff, K; Tomson, T, 2020) |
| "Adverse drug reactions are a leading cause of treatment failure with antiepileptic drugs." | 1.51 | Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs. ( Jiang, Y; Tan, NC; Wu, Y; Zhang, Z, 2019) |
| "This open-label, single-sequence study in healthy subjects investigated the effects of steady-state carbamazepine on the pharmacokinetic (PK) profile of a single 2-mg dose of fingolimod." | 1.48 | Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects. ( Behrje, R; David, OJ; Hara, H; Lates, CD; Pal, P; Schmouder, R, 2018) |
| "Adverse drug reactions have been linked with genetic polymorphisms in HLA genes in numerous different studies." | 1.48 | Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions. ( Carr, DF; Jones, AR; Ramsbottom, KA; Rigden, DJ, 2018) |
| "Oxcarbazepine (OXC) is a 10-keto analogue of carbamazepine used in patients with partial and secondary generalized seizures." | 1.43 | Thirteen years of oxcarbazepine exposures reported to US poison centers: 2000 to 2012. ( Burns, G; Essing-Spiller, SJ; Spiller, HA; Strauch, J, 2016) |
| "Allopurinol treatment, based on screening by HLA-B*58:01 genotyping, could be more cost-effective than that not based on screening." | 1.43 | HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. ( Kim, DH; Kim, J; Kim, YJ; Lee, JH; Park, HJ; Park, JW; Park, KH, 2016) |
| "All patients ≥16years of age with epilepsy for ≥12months were routinely asked to complete the Liverpool Adverse Event Profile (LAEP) just before their appointment." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| " In this research, we have explored the feasibility of retrospectively mapping population-level adverse events from the FDA Adverse Event Reporting System (FAERS) to chemical and biological databases to identify drug safety signals and the underlying molecular mechanisms." | 1.43 | Improving drug safety with a systems pharmacology approach. ( Bojunga, N; Lesko, LJ; Schotland, P; Trame, MN; Zien, A, 2016) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| "Carbamazepine use was associated with a nearly 10-fold increase in severe cutaneous drug reactions in Korean elderly patients." | 1.39 | Multi-indication carbamazepine and the risk of severe cutaneous adverse drug reactions in Korean elderly patients: a Korean health insurance data-based study. ( Choi, NK; Jung, SY; Kim, JY; Ko, YJ; Lee, J; Park, BJ; Shin, JY, 2013) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "There were no serious adverse drug reactions reported during this study." | 1.36 | Safety profile of oxcarbazepine: results from a prescription-event monitoring study. ( Buggy, Y; Fogg, C; Layton, D; Shakir, SA, 2010) |
| " FK506 dosing required a 1." | 1.35 | Drug interaction between tacrolimus and carbamazepine in a Japanese heart transplant recipient: a case report. ( Kato, TS; Komamura, K; Kotake, T; Mano, A; Morishita, H; Nakatani, T; Ochi, H; Oda, N; Okada, H; Sakai, M; Takada, M; Wada, K, 2009) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (8.42) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (13.68) | 29.6817 |
| 2010's | 62 (65.26) | 24.3611 |
| 2020's | 12 (12.63) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 2 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Mushiroda, T | 3 |
| Shirayanagi, T | 1 |
| Kazaoka, A | 1 |
| Watanabe, K | 1 |
| Qu, L | 1 |
| Sakamoto, N | 1 |
| Hoshino, T | 1 |
| Ito, K | 1 |
| Aoki, S | 1 |
| Green, SF | 1 |
| Hare, N | 1 |
| Kassam, M | 1 |
| Rugg-Gunn, F | 1 |
| Koepp, MJ | 1 |
| Sander, JW | 1 |
| Rajakulendran, S | 1 |
| Uwai, Y | 1 |
| Nabekura, T | 1 |
| Zhang, Z | 1 |
| Wu, Y | 1 |
| Tan, NC | 1 |
| Jiang, Y | 1 |
| Shen, M | 1 |
| Lim, JME | 1 |
| Chia, C | 1 |
| Ren, EC | 2 |
| Rocamora, R | 1 |
| Peltola, J | 1 |
| Assenza, G | 1 |
| McMurray, R | 1 |
| Villanueva, V | 1 |
| Lee, JE | 1 |
| Min, KR | 1 |
| Kim, SH | 1 |
| Kim, AH | 1 |
| Kim, ST | 1 |
| Åndell, E | 1 |
| Tomson, T | 1 |
| Åmark, P | 1 |
| Pihlström, N | 1 |
| Tedroff, K | 1 |
| Carlsson, S | 1 |
| Shiohara, T | 2 |
| Müller, RM | 1 |
| Herziger, B | 1 |
| Jeschke, S | 1 |
| Neininger, MP | 1 |
| Bertsche, T | 1 |
| Bertsche, A | 1 |
| Jang, Y | 1 |
| Yoon, S | 1 |
| Kim, TJ | 1 |
| Lee, S | 1 |
| Yu, KS | 1 |
| Jang, IJ | 1 |
| Chu, K | 1 |
| Lee, SK | 1 |
| Jeiziner, C | 1 |
| Wernli, U | 1 |
| Suter, K | 1 |
| Hersberger, KE | 1 |
| Meyer Zu Schwabedissen, HE | 1 |
| Fricke-Galindo, I | 2 |
| LLerena, A | 2 |
| López-López, M | 2 |
| Yu, M | 1 |
| Tan-Koi, WC | 1 |
| Sung, C | 1 |
| Chong, YY | 1 |
| Lateef, A | 1 |
| Pang, SM | 1 |
| Vasudevan, A | 1 |
| Aw, D | 1 |
| Lui, NL | 1 |
| Lee, SX | 1 |
| Koay, ES | 1 |
| Tay, YK | 1 |
| Lim, YL | 1 |
| Lee, HY | 1 |
| Dong, D | 1 |
| Loke, C | 1 |
| Tan, L | 1 |
| Limenta, M | 1 |
| Lee, EJ | 1 |
| Toh, D | 1 |
| Chan, CL | 1 |
| Illing, PT | 1 |
| Purcell, AW | 1 |
| McCluskey, J | 1 |
| Albright, A | 1 |
| Way, RT | 1 |
| Häfele, CA | 1 |
| Freitas, MP | 1 |
| Gervini, BL | 1 |
| de Carvalho, RM | 1 |
| Rombaldi, AJ | 1 |
| Phillips, EJ | 2 |
| Sukasem, C | 2 |
| Whirl-Carrillo, M | 1 |
| Müller, DJ | 1 |
| Dunnenberger, HM | 1 |
| Chantratita, W | 1 |
| Goldspiel, B | 1 |
| Chen, YT | 3 |
| Carleton, BC | 1 |
| George, AL | 1 |
| Klein, T | 1 |
| Gammal, RS | 1 |
| Pirmohamed, M | 4 |
| Usui, T | 1 |
| Faulkner, L | 1 |
| Farrell, J | 1 |
| French, NS | 1 |
| Alfirevic, A | 2 |
| Park, BK | 1 |
| Naisbitt, DJ | 1 |
| Shorvon, SD | 1 |
| Bermejo, PE | 1 |
| Gibbs, AA | 1 |
| Huberfeld, G | 1 |
| Kälviäinen, R | 1 |
| He, Y | 1 |
| Seminario-Vidal, L | 1 |
| McLeod, HL | 1 |
| Liu, Y | 1 |
| Yu, Y | 1 |
| Nie, X | 1 |
| Zhao, L | 1 |
| Wang, X | 1 |
| David, OJ | 1 |
| Behrje, R | 1 |
| Pal, P | 1 |
| Hara, H | 1 |
| Lates, CD | 1 |
| Schmouder, R | 1 |
| Ramsbottom, KA | 1 |
| Carr, DF | 1 |
| Jones, AR | 1 |
| Rigden, DJ | 1 |
| Simper, GS | 1 |
| Hò, GT | 1 |
| Celik, AA | 1 |
| Huyton, T | 1 |
| Kuhn, J | 1 |
| Kunze-Schumacher, H | 1 |
| Blasczyk, R | 1 |
| Bade-Döding, C | 1 |
| Koristkova, B | 1 |
| Grundmann, M | 1 |
| Brozmanova, H | 1 |
| Kacirova, I | 1 |
| de Graaff, LC | 1 |
| van Schaik, RH | 1 |
| van Gelder, T | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| Rattanavipapong, W | 1 |
| Koopitakkajorn, T | 1 |
| Praditsitthikorn, N | 1 |
| Mahasirimongkol, S | 1 |
| Teerawattananon, Y | 1 |
| Wang, Q | 1 |
| Mei, H | 1 |
| Zhang, YL | 1 |
| Pan, XC | 1 |
| Tan, W | 1 |
| Chao, L | 1 |
| Chong, KW | 1 |
| Chan, DW | 1 |
| Cheung, YB | 1 |
| Ching, LK | 1 |
| Hie, SL | 1 |
| Thomas, T | 1 |
| Ling, S | 1 |
| Tan, EC | 1 |
| Kim, JY | 1 |
| Lee, J | 1 |
| Ko, YJ | 1 |
| Shin, JY | 1 |
| Jung, SY | 1 |
| Choi, NK | 1 |
| Park, BJ | 1 |
| Jaramillo, NM | 1 |
| Galindo, IF | 1 |
| Vázquez, AO | 1 |
| Cook, HJ | 1 |
| López, ML | 1 |
| Miguel, A | 1 |
| Henriques, F | 1 |
| Azevedo, LF | 1 |
| Pereira, AC | 1 |
| Chen, Z | 1 |
| Liew, D | 1 |
| Kwan, P | 2 |
| Thorstensen, K | 1 |
| Kvitland, M | 1 |
| Shirzadi, M | 1 |
| Helde, G | 1 |
| Moen, T | 1 |
| Brodtkorb, E | 1 |
| Xiong, Y | 1 |
| Zhang, W | 1 |
| Chen, X | 1 |
| Martínez-Juárez, IE | 1 |
| Monroy-Jaramillo, N | 1 |
| Jung-Cook, H | 1 |
| Falfán-Valencia, R | 1 |
| Ortega-Vázquez, A | 1 |
| Alonso-Vilatela, ME | 1 |
| Lee, D | 2 |
| Kalu, U | 1 |
| Halford, JJ | 1 |
| Biton, V | 2 |
| Cloyd, J | 2 |
| Klein, P | 1 |
| Bekersky, I | 2 |
| Peng, G | 1 |
| Dheerendra, S | 1 |
| Tolbert, D | 2 |
| Walzer, M | 1 |
| Wesche, D | 1 |
| Drummond, R | 1 |
| Plumpton, CO | 1 |
| Yip, VL | 1 |
| Marson, AG | 1 |
| Hughes, DA | 1 |
| Kamijo, Y | 1 |
| Spiller, HA | 1 |
| Strauch, J | 1 |
| Essing-Spiller, SJ | 1 |
| Burns, G | 1 |
| Park, HJ | 1 |
| Kim, YJ | 1 |
| Kim, DH | 1 |
| Kim, J | 1 |
| Park, KH | 1 |
| Park, JW | 1 |
| Lee, JH | 2 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Jaruthamsophon, K | 1 |
| Sripo, T | 1 |
| Limprasert, P | 1 |
| Schotland, P | 1 |
| Bojunga, N | 1 |
| Zien, A | 1 |
| Trame, MN | 1 |
| Lesko, LJ | 1 |
| Churchwell, MD | 1 |
| Pasko, DA | 1 |
| Smoyer, WE | 1 |
| Mueller, BA | 1 |
| Wada, K | 1 |
| Takada, M | 1 |
| Sakai, M | 1 |
| Ochi, H | 1 |
| Kotake, T | 1 |
| Okada, H | 1 |
| Morishita, H | 1 |
| Oda, N | 1 |
| Mano, A | 1 |
| Kato, TS | 1 |
| Komamura, K | 1 |
| Nakatani, T | 1 |
| Buggy, Y | 1 |
| Layton, D | 1 |
| Fogg, C | 1 |
| Shakir, SA | 1 |
| Joshi, G | 1 |
| Wozniak, J | 1 |
| Mick, E | 1 |
| Doyle, R | 1 |
| Hammerness, P | 1 |
| Georgiopoulos, A | 1 |
| Kotarski, M | 1 |
| Aleardi, M | 1 |
| Williams, C | 1 |
| Walls, S | 1 |
| Biederman, J | 1 |
| Kim, WJ | 1 |
| Yi, J | 1 |
| Cho, YJ | 1 |
| Heo, K | 1 |
| Lee, SH | 1 |
| Kim, SW | 1 |
| Kim, MK | 1 |
| Kim, KH | 1 |
| In Lee, B | 1 |
| Lee, MG | 1 |
| Santucci, R | 1 |
| Fothergill, H | 1 |
| Laugel, V | 1 |
| Perville, A | 1 |
| De Saint Martin, A | 1 |
| Gerout, AC | 1 |
| Fischbach, M | 1 |
| Hung, SI | 3 |
| Chung, WH | 3 |
| Liu, ZS | 1 |
| Chen, CH | 2 |
| Hsih, MS | 1 |
| Hui, RC | 2 |
| Chu, CY | 1 |
| Niederhofer, H | 1 |
| Waszkielewicz, A | 1 |
| Szkaradek, N | 1 |
| Pękala, E | 1 |
| Galzarano, F | 1 |
| Marona, H | 1 |
| Kamiguchi, N | 1 |
| Aoyama, E | 1 |
| Okuda, T | 1 |
| Moriwaki, T | 1 |
| Wu, XT | 1 |
| Hu, FY | 1 |
| An, DM | 1 |
| Yan, B | 1 |
| Jiang, X | 1 |
| Stefan, H | 1 |
| Zhou, D | 1 |
| Ozeki, T | 1 |
| Yowang, A | 1 |
| Takahashi, A | 1 |
| Kubo, M | 1 |
| Shirakata, Y | 1 |
| Ikezawa, Z | 1 |
| Iijima, M | 1 |
| Hashimoto, K | 1 |
| Kamatani, N | 1 |
| Nakamura, Y | 1 |
| Chen, P | 2 |
| Lin, JJ | 1 |
| Lu, CS | 1 |
| Ong, CT | 1 |
| Hsieh, PF | 1 |
| Yang, CC | 1 |
| Tai, CT | 1 |
| Wu, SL | 1 |
| Lu, CH | 1 |
| Hsu, YC | 1 |
| Yu, HY | 1 |
| Ro, LS | 1 |
| Lu, CT | 1 |
| Chu, CC | 1 |
| Tsai, JJ | 1 |
| Su, YH | 1 |
| Lan, SH | 1 |
| Sung, SF | 1 |
| Lin, SY | 1 |
| Chuang, HP | 1 |
| Huang, LC | 1 |
| Chen, YJ | 1 |
| Tsai, PJ | 1 |
| Liao, HT | 1 |
| Lin, YH | 1 |
| Wu, JY | 1 |
| Chang, CF | 1 |
| Shen, CY | 1 |
| Wang, S | 1 |
| Gunsch, CK | 1 |
| Ram Prabahar, M | 1 |
| Raja Karthik, K | 1 |
| Singh, M | 1 |
| Singh, RB | 1 |
| Singh, S | 1 |
| Dhamodharan, J | 1 |
| Kulkantrakorn, K | 1 |
| Tassaneeyakul, W | 1 |
| Tiamkao, S | 1 |
| Jantararoungtong, T | 1 |
| Prabmechai, N | 1 |
| Vannaprasaht, S | 1 |
| Chumworathayi, P | 1 |
| Sritipsukho, P | 1 |
| Daly, AK | 1 |
| Liao, WP | 1 |
| Shi, YW | 1 |
| Min, FL | 1 |
| Mallal, SA | 1 |
| Lin, YT | 1 |
| Chang, YC | 1 |
| Yang, CH | 1 |
| Ho, HC | 1 |
| Sikma, MA | 1 |
| van den Broek, MP | 1 |
| Meulenbelt, J | 1 |
| Ferrari, B | 1 |
| Mons, R | 1 |
| Vollat, B | 1 |
| Fraysse, B | 1 |
| Paxéus, N | 1 |
| Lo Giudice, R | 1 |
| Pollio, A | 1 |
| Garric, J | 1 |
| Fountoulakis, M | 1 |
| Drillia, P | 1 |
| Stamatelatou, K | 1 |
| Lyberatos, G | 2 |
| Dokianakis, SN | 1 |
| Kornaros, ME | 1 |
| Lin, MS | 1 |
| Dai, YS | 1 |
| Pwu, RF | 1 |
| Chen, YH | 1 |
| Chang, NC | 1 |
| Shinnar, S | 1 |
| Pellock, JM | 1 |
| Haas, SJ | 1 |
| Koh, KH | 1 |
| Tan, HH | 1 |
| Puhó, EH | 1 |
| Szunyogh, M | 1 |
| Métneki, J | 1 |
| Czeizel, AE | 1 |
| Lyszkiewicz, DA | 1 |
| Gerichhausen, S | 1 |
| Björnsdóttir, I | 1 |
| Einarson, TR | 1 |
| Koren, G | 1 |
| Einarson, A | 1 |
| Hammond, KB | 1 |
| Gehlen, W | 1 |
| von Wichert, P | 1 |
| Windorfer, A | 1 |
| Stünkel, S | 1 |
| Cramarossa, L | 1 |
| D'Angelo, D | 1 |
| Galassi, A | 1 |
| Puletti, M | 1 |
| Parsonage, M | 1 |
| Moses, AM | 1 |
| Miller, M | 1 |
| Jacobs, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study[NCT03184597] | 4,000 participants (Anticipated) | Interventional | 2017-08-01 | Recruiting | |||
| A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy[NCT01079351] | Phase 1 | 98 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy[NCT01128959] | Phase 3 | 108 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency[NCT01379469] | Phase 2 | 20 participants (Actual) | Interventional | 2012-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01128959)
Timeframe: Baseline to after last iv dose on day 4
| Intervention | Number of adverse events (Number) |
|---|---|
| Intravenous Carbamazepine (IV CBZ) 15 Minutes Infusion | 126 |
| Intravenous Carbamazepine (IV CBZ) 5 Minutes Infusion | 26 |
17 reviews available for carbamazepine and Adverse Drug Event
| Article | Year |
|---|---|
Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Humans; Lamotrigine | 2023 |
HLA-associated adverse drug reactions - scoping review.
Topics: Alleles; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Genetic Predisposition to D | 2021 |
An update on HLA alleles associated with adverse drug reactions.
Topics: Alleles; Allopurinol; Carbamazepine; Dideoxynucleosides; Drug-Related Side Effects and Adverse React | 2017 |
The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.
Topics: Allopurinol; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Haptens; HLA Antigens; | 2017 |
Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Drug and Narcotic Control; Drug-Related Side Effect | 2018 |
Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis.
Topics: Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Female; HLA-B15 Antigen; H | 2018 |
[The associations between idiosyncratic adverse drug reactions and HLA alleles and their underlying mechanism].
Topics: Alleles; Allopurinol; Anti-HIV Agents; Anticonvulsants; Carbamazepine; Dideoxynucleosides; Drug Hype | 2013 |
Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.
Topics: Anticonvulsants; ATP-Binding Cassette Transporters; Carbamazepine; Cytochrome P-450 Enzyme System; D | 2014 |
Ophthalmic adverse drug reactions to systemic drugs: a systematic review.
Topics: Animals; Carbamazepine; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Eye Disease | 2014 |
[Pharmacogenetic research in the association between human leukocyte antigen and adverse drug reactions].
Topics: Allopurinol; Carbamazepine; Dideoxynucleosides; Drug-Related Side Effects and Adverse Reactions; Gen | 2014 |
[Acute Drug Poisoning: Focus on Psychotropic Drugs].
Topics: Carbamazepine; Charcoal; Drug-Related Side Effects and Adverse Reactions; Humans; Lithium; Psychoses | 2015 |
Successful treatment of carbamazepine poisoning with hemodialysis: a case report and review of the literature.
Topics: Adult; Analgesics, Non-Narcotic; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Fem | 2011 |
Using genome-wide association studies to identify genes important in serious adverse drug reactions.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamazepine; Chemical and Drug Induced Liver Injury; Cytochrome P-4 | 2012 |
Drugs and children: methods for therapeutic monitoring.
Topics: Carbamazepine; Child; Child, Preschool; Chloramphenicol; Chromatography, Gas; Colorimetry; Drug Ther | 1977 |
[Iatrogenic damage possibilities in the drug therapy of neurologic and psychiatric diseases].
Topics: Amantadine; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Central Nervous System Di | 1977 |
[Drugs and the thyroid gland].
Topics: Adrenergic beta-Antagonists; Amiodarone; Carbamazepine; Danazol; Drug-Related Side Effects and Adver | 1987 |
Drug-induced dilutional hyponatremia.
Topics: Acetaminophen; Amitriptyline; Animals; Anura; Body Fluids; Carbamazepine; Chlorpropamide; Clofibrate | 1974 |
4 trials available for carbamazepine and Adverse Drug Event
| Article | Year |
|---|---|
Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials.
Topics: Administration, Oral; Adult; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug-Rela | 2015 |
Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials.
Topics: Administration, Oral; Adult; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug-Rela | 2015 |
Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials.
Topics: Administration, Oral; Adult; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug-Rela | 2015 |
Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials.
Topics: Administration, Oral; Adult; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug-Rela | 2015 |
Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Area Under Curve; Carbamazepine; Drug-Related Si | 2015 |
A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder.
Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Body Weight; Carb | 2010 |
Clinical evaluation of side-effects of drugs.
Topics: Accident Prevention; Aged; Anti-Bacterial Agents; Anticoagulants; Carbamazepine; Dibenzazepines; Dru | 1973 |
74 other studies available for carbamazepine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Weak complex formation of adverse drug reaction-associated HLAB57, B58, and B15 molecules.
Topics: Carbamazepine; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; HLA Antigens; | 2022 |
Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Drug Therapy, Combination; Drug-Related Sid | 2022 |
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug | 2022 |
Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Humans; Literacy; P | 2019 |
CD39
Topics: Adenosine; Allergens; Antigens, CD; Apyrase; Carbamazepine; Case-Control Studies; Cells, Cultured; D | 2020 |
Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Clinical Studies as Topi | 2020 |
Analysis of Adverse Drug Reactions with Carbamazepine and Oxcarbazepine at a Tertiary Care Hospital.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bipolar Disorder; Carbamazepine; Drug-Related Side Effects | 2020 |
Childhood-onset seizures: A long-term cohort study of use of antiepileptic drugs, and drugs for neuropsychiatric conditions.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Comorbidity; Drug-Related Side | 2020 |
Commentary on "The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA" by W-H Chung et al.
Topics: Carbamazepine; Drug-Related Side Effects and Adverse Reactions; HLA-B Antigens; Humans | 2021 |
Knowledge of epilepsy among German pharmacists.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; L | 2021 |
Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Diplopia; Dizziness; Dru | 2021 |
Coding for Medication-related Poisoning and Adverse Effects.
Topics: Adult; Carbamazepine; Documentation; Drug-Related Side Effects and Adverse Reactions; Female; Humans | 2017 |
Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.
Topics: Alleles; Allopurinol; Carbamazepine; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Re | 2017 |
Lithium toxicity and prolonged delirium.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepine; Delirium; Depression; Dose | 2017 |
Who are the individuals diagnosed with epilepsy using the Public Health System in the city of Pelotas, southern Brazil?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Anxiety; Brazil; Carbamazepine; Child; Cross-Sectional Stu | 2018 |
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; HLA-B Antigens; Hum | 2018 |
Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity.
Topics: Anti-Infective Agents; Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactio | 2018 |
Avoidance of Severe Cutaneous Adverse Drug Events as a First Step in Precision Neurology.
Topics: Carbamazepine; Drug-Related Side Effects and Adverse Reactions; HLA-A Antigens; Humans; Incidence; J | 2018 |
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects.
Topics: Adolescent; Adult; Area Under Curve; Carbamazepine; Dose-Response Relationship, Drug; Drug Administr | 2018 |
Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions.
Topics: Alleles; Carbamazepine; Dideoxynucleosides; Drug-Related Side Effects and Adverse Reactions; HLA Ant | 2018 |
Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02.
Topics: Allergens; Anticonvulsants; Antigen Presentation; B-Lymphocytes; Binding Sites; Carbamazepine; Cell | 2018 |
Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Czech Republic; Dose-Response R | 2019 |
A clinical approach to pharmacogenetics.
Topics: Carbamazepine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Genotype; Humans; | 2013 |
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Epilepsy; HL | 2013 |
Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.
Topics: Adolescent; Alleles; Anticonvulsants; Carbamazepine; Case-Control Studies; Child; Child, Preschool; | 2014 |
Multi-indication carbamazepine and the risk of severe cutaneous adverse drug reactions in Korean elderly patients: a Korean health insurance data-based study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Case-Control Studies; Databases, Factual; D | 2013 |
Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions.
Topics: Aged; Asian People; Carbamazepine; Costs and Cost Analysis; Drug-Related Side Effects and Adverse Re | 2014 |
Carbamazepine-induced cutaneous reactions: a simple assay to identify patients carrying the HLA-A*31:01 allele.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Genetic Markers; Ge | 2014 |
HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients.
Topics: Adolescent; Adult; Aged; Carbamazepine; Drug Eruptions; Drug-Related Side Effects and Adverse Reacti | 2014 |
Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Cost-Benefit Analysis; Decision Trees; Drug-Related Side Effe | 2015 |
Thirteen years of oxcarbazepine exposures reported to US poison centers: 2000 to 2012.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Overdose; Drug-Rela | 2016 |
HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.
Topics: Adult; Aged; Alleles; Allopurinol; Anticonvulsants; Asian People; Carbamazepine; Case-Control Studie | 2016 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions.
Topics: Alleles; Asian People; Carbamazepine; Case-Control Studies; Drug Hypersensitivity; Drug-Related Side | 2016 |
Improving drug safety with a systems pharmacology approach.
Topics: Acetaminophen; Adverse Drug Reaction Reporting Systems; Analgesics, Non-Narcotic; Anticonvulsants; C | 2016 |
Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis.
Topics: Albumins; Animals; Carbamazepine; Cattle; Drug-Related Side Effects and Adverse Reactions; Hemodialy | 2009 |
Drug interaction between tacrolimus and carbamazepine in a Japanese heart transplant recipient: a case report.
Topics: Adult; Anticonvulsants; Carbamazepine; Cardiomyopathy, Dilated; Drug Therapy, Combination; Drug-Rela | 2009 |
Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Carbamazepine; | 2010 |
A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.
Topics: Alleles; Anticonvulsants; Carbamazepine; Case-Control Studies; Cell Line; Central Nervous System; Dr | 2010 |
The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy.
Topics: Carbamazepine; Child; Clarithromycin; Dose-Response Relationship, Drug; Drug Interactions; Drug Ther | 2010 |
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Anticonvulsants; Asian People; Carbamazepine; C | 2010 |
Combining atomoxetine with carbamazepine or neuroleptics reduces adverse side effects.
Topics: Adrenergic Uptake Inhibitors; Anticonvulsants; Antipsychotic Agents; Atomoxetine Hydrochloride; Carb | 2010 |
The study of the lipophilicity of some aminoalkanol derivatives with anticonvulsant activity.
Topics: Animals; Anticonvulsants; Carbamazepine; Chromatography, Reverse-Phase; Chromatography, Thin Layer; | 2010 |
A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes.
Topics: Biological Assay; Carbamazepine; Cell Culture Techniques; Cell Membrane; Cells, Cultured; Cryopreser | 2010 |
Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China.
Topics: Adolescent; Adult; Aged, 80 and over; Anticonvulsants; Carbamazepine; Chi-Square Distribution; Child | 2010 |
Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Anticonvulsants; Asian People; Carbamazepine; C | 2011 |
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Asian People; Carbamazepine; Child; Chi | 2011 |
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Asian People; Carbamazepine; Child; Chi | 2011 |
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Asian People; Carbamazepine; Child; Chi | 2011 |
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Asian People; Carbamazepine; Child; Chi | 2011 |
Effects of selected pharmaceutically active compounds on treatment performance in sequencing batch reactors mimicking wastewater treatment plants operations.
Topics: Bacteria; Biodiversity; Bioreactors; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; | 2011 |
HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
Topics: Adult; Aged; Alleles; Analgesics, Non-Narcotic; Carbamazepine; Case-Control Studies; Drug-Related Si | 2012 |
HLA-B*1502 screening and toxic effects of carbamazepine.
Topics: Anticonvulsants; Asian People; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Genot | 2011 |
HLA-B*1502 screening and toxic effects of carbamazepine.
Topics: Anticonvulsants; Asian People; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; HLA-B | 2011 |
A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions.
Topics: Carbamazepine; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Humans; Patch | 2013 |
Increased unbound drug fraction in acute carbamazepine intoxication: suitability and effectiveness of high-flux haemodialysis.
Topics: Anticonvulsants; Carbamazepine; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Fema | 2012 |
Genetics and the potential for predictive tests in adverse drug reactions.
Topics: Allopurinol; Anti-Bacterial Agents; Anti-HIV Agents; Anticonvulsants; Antimetabolites; Biomarkers; C | 2012 |
Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?
Topics: Animals; Carbamazepine; Clofibric Acid; Diclofenac; Drug-Related Side Effects and Adverse Reactions; | 2004 |
Toxic effect of pharmaceuticals on methanogenesis.
Topics: Bacteria, Anaerobic; Biomass; Carbamazepine; Clofibric Acid; Diclofenac; Drug-Related Side Effects a | 2004 |
On the effect of pharmaceuticals on bacterial nitrite oxidation.
Topics: Bacteria, Anaerobic; Biodegradation, Environmental; Bioreactors; Carbamazepine; Cities; Clofibrate; | 2004 |
Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study.
Topics: Adult; Allopurinol; Analgesics, Non-Narcotic; Anticonvulsants; Antimetabolites; Carbamazepine; Case- | 2005 |
The trials and tribulations of pediatric drug trials.
Topics: Age Factors; Anticonvulsants; Brain; Carbamazepine; Child; Clinical Trials as Topic; Drug-Related Si | 2005 |
Adverse drug reaction reporting and pharmacovigilance of new therapeutic agents.
Topics: Acidosis; Adverse Drug Reaction Reporting Systems; Anticonvulsants; Carbamazepine; Communication; Co | 2006 |
High-flux haemodialysis treatment as treatment for carbamazepine intoxication.
Topics: Acute Disease; Adult; Anticonvulsants; Carbamazepine; Drug Monitoring; Drug-Related Side Effects and | 2006 |
Drug treatment during pregnancy and isolated orofacial clefts in hungary.
Topics: Abnormalities, Drug-Induced; Adrenergic beta-Antagonists; Amoxicillin; Anti-Bacterial Agents; Antico | 2007 |
Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antitrichomonal Agents; Canada; Ca | 2001 |
[Drug side-effects in the lung].
Topics: Antineoplastic Agents; Asthma; Carbamazepine; Cromolyn Sodium; Drug-Related Side Effects and Adverse | 1978 |
[Significance of pharmacogenic liver reactions for metabolism of endogenous and exogenous substances].
Topics: Carbamazepine; Diazepam; Drug-Related Side Effects and Adverse Reactions; Female; Fenoterol; Humans; | 1979 |
Epilepsy.
Topics: Adrenocorticotropic Hormone; Carbamazepine; Diazepam; Drug Hypersensitivity; Drug-Related Side Effec | 1974 |